RT Journal Article SR Electronic T1 Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer JF Cancer Genomics - Proteomics JO Cancer Genomics Proteomics FD International Institute of Anticancer Research SP 151 OP 160 VO 13 IS 2 A1 XUAN CHEN A1 YUE LIU A1 JIAN WU A1 HUARONG HUANG A1 ZHIYUN DU A1 KUN ZHANG A1 DAIYING ZHOU A1 KAYLYN HUNG A1 SUSAN GOODIN A1 XI ZHENG YR 2016 UL http://cgp.iiarjournals.org/content/13/2/151.abstract AB Aim: To investigate the effects and mechanisms of docetaxel and atorvastatin administered individually or in combination on prostate cancer cells. Materials and Methods: Cell growth and apoptosis were determined by the trypan blue exclusion assay and morphological assessment of cells was performed with propidium iodide. NF-κB activity was determined by luciferase reporter gene assay and the western blot assay was used to determine the levels of Bcl-2, phospho-Akt, VEGF, and phospho-Erk1/2. Results: Results showed that following pre-treatment with cholesterol, resistance of PC-3 prostate cancer cells to docetaxel was increased. The combination of docetaxel with atorvastatin potently inhibited growth and induced apoptosis in PC-3 cells. Mechanistic studies indicated that induction of apoptosis in PC-3 cells was associated with significant decreases in the levels of Bcl-2, VEGF, phosphor-Akt, and phosphor-Erk1/2. Conclusion: Treatment with cholesterol decreased the sensitivity of prostate cancer cells to docetaxel. Docetaxel in combination with cholesterol-lowering drugs such as atorvastatin may be an effective strategy for inhibiting the growth of prostate cancer.